Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4754657 | 0.71 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL283475 | 0.67 | ALDH1A1 (0.48) | ALDH1A1TSHRCHRNB2CHRNB4CHRNA4 | |
| SCHEMBL1191256 | 0.67 | ALDH1A1 (0.63) | ALDH1A1TSHRCHRNB2CHRNB4CHRNA4 | |
| SCHEMBL26455366 | 0.65 | ALDH1A1 (0.46) | ALDH1A1TSHRCHRNB2CHRNB4CHRNA4 | |
| SCHEMBL2785008 | 0.65 | — | — | |
| SCHEMBL6526896 | 0.65 | — | — | |
| SCHEMBL9640 | 0.65 | — | — | |
| SCHEMBL97330 | 0.65 | — | — | |
| SCHEMBL442427 | 0.65 | — | — | |
| SCHEMBL1193 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253634-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ALLERGAN GI CORP (US) | 2021-08-19 | — | — | US | claimed |
| US-20200172572-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ALLERGAN GI CORP (US) | 2020-06-04 | — | — | US | claimed |
| US-20170218015-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ALLERGAN GI CORP. | 2017-08-03 | — | — | US | claimed |
| EP-3114132-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | MOTUS THERAPEUTICS, INC. (US) | 2017-01-11 | — | — | EP | claimed |
| WO-2015134567-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | RHYTHM PHARMACEUTICALS, INC. (US) | 2015-09-11 | — | — | WO | claimed |
| US-11911475-B2 | Low molecular weight cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11911475-B2 | Low molecular weight cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230000989-A1 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | SIRNA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| US-11413348-B2 | Low molecular weight cationic lipids for oligonucleotide delivery | SIRNA THEREPEUTICS, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-11332745-B2 | RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (SINA) | SIMA THERAPEUTICS, INC. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20210253634-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ALLERGAN GI CORP (US) | 2021-08-19 | — | — | US | disclosed |
| EP-3144015-B1 | LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | SIRNA THERAPEUTICS INC (US) | 2021-06-02 | — | — | EP | disclosed |
| US-20130178541-A1 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | BANK OF AMERICA, N.A. | 2013-07-11 | — | — | US | disclosed |
| US-20130178541-A1 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | BANK OF AMERICA, N.A. | 2013-07-11 | — | — | US | disclosed |
| US-20130165500-A1 | RNA Interference Mediated Inhibition of Prolyl Hydroxylase Domain 2 (PHD2) Gene Expression Using Short Interfering Nucleic Acid (siNA) | BANK OF AMERICA, N.A. | 2013-06-27 | — | — | US | disclosed |
| US-20130165500-A1 | RNA Interference Mediated Inhibition of Prolyl Hydroxylase Domain 2 (PHD2) Gene Expression Using Short Interfering Nucleic Acid (siNA) | BANK OF AMERICA, N.A. | 2013-06-27 | — | — | US | disclosed |
| US-20130150433-A1 | RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV) Gene Expression Using Short Interfering Nucleic Acid (siNA) | BANK OF AMERICA, N.A. | 2013-06-13 | — | — | US | disclosed |
| US-20130150433-A1 | RNA Interference Mediated Inhibition of Hepatitis B Virus (HBV) Gene Expression Using Short Interfering Nucleic Acid (siNA) | BANK OF AMERICA, N.A. | 2013-06-13 | — | — | US | disclosed |
| US-20130137752-A1 | RNA Interference Mediated Inhibition of Catenin (Cadherin-Associated Protein), Beta 1 (CTNNB1) Gene Expression Using Short Interfering Nucleic Acid (siNA) | BANK OF AMERICA, N.A. | 2013-05-30 | — | — | US | disclosed |
| US-20130137752-A1 | RNA Interference Mediated Inhibition of Catenin (Cadherin-Associated Protein), Beta 1 (CTNNB1) Gene Expression Using Short Interfering Nucleic Acid (siNA) | BANK OF AMERICA, N.A. | 2013-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165500-A1 | RNA Interference Mediated Inhibition of Prolyl Hydroxylase Domain 2 (PHD2) Gene Expression Using Short Interfering Nucleic Acid (siNA) | EGLN2, AGO2, EGLN3 | ALDH1A1 1527/4885TSHR 2154/4885L3MBTL1 1565/4885 |
| US-20210253634-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | VIP, IAPP, PROKR1 | ALDH1A1 3729/4885TSHR 986/4885L3MBTL1 3469/4885 |
| US-20200172572-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | VIP, IAPP, PROKR1 | ALDH1A1 3729/4885TSHR 986/4885L3MBTL1 3469/4885 |
| US-20170218015-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | VIP, IAPP, PROKR1 | ALDH1A1 3729/4885TSHR 986/4885L3MBTL1 3469/4885 |
| US-20230000989-A1 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | LDLR, LIPC, CETP | ALDH1A1 3743/4885TSHR 1936/4885L3MBTL1 172/4885 |
| US-20130178541-A1 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | LDLR, LIPC, CETP | ALDH1A1 3743/4885TSHR 1936/4885L3MBTL1 172/4885 |
| US-11332745-B2 | RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (SINA) | EGLN2, EGLN3, EGLN1 | ALDH1A1 1024/4885TSHR 4513/4885L3MBTL1 1287/4885 |
| US-11911475-B2 | Low molecular weight cationic lipids for oligonucleotide delivery | LDLR, APOB, CETP | ALDH1A1 4090/4885TSHR 1415/4885L3MBTL1 136/4885 |
| US-11413348-B2 | Low molecular weight cationic lipids for oligonucleotide delivery | LDLR, APOB, CETP | ALDH1A1 4090/4885TSHR 1415/4885L3MBTL1 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.